|
Diabetes, Vol 49, Issue 5 735-740, Copyright © 2000 by American Diabetes Association
Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells
G Patane, S Piro, AM Rabuazzo, M Anello, R Vigneri and F Purrello
Department of Internal Medicine, Signorelli Diabetes Center, University of Catania, Ospedale Garibaldi, Italy.
Because metformin affects glucose and free fatty acid (FFA) metabolism in
peripheral insulin target tissues, we investigated the effect of this drug
in restoring a normal secretory pattern in rat pancreatic islets whose
function has been impaired by chronic exposure to elevated FFA or glucose
concentrations. We cultured rat pancreatic islets with or without FFA (2
mmol/l oleate/palmitate 2:1) or high glucose (16.7 mmol/l) concentrations
in the presence or absence of metformin (0.25-12.5 microg/ml) and then
measured insulin release, glucose utilization, glucose, and FFA oxidation.
When compared with control islets, islets exposed to high FFA or glucose
concentrations showed an increased basal and a decreased glucose-induced
insulin release. In islets cultured for an additional 24 h with FFA or
glucose in the presence of metformin (2.5 microg/ml), both basal and
glucose-induced insulin secretions were restored. Both glucose utilization
and glucose oxidation were altered in islets pre-exposed to high FFA or
glucose concentrations. In particular, regarding control islets, glucose
utilization was increased at 2.8 mmol/l glucose and decreased at 16.7
mmol/l glucose; glucose oxidation was similar to control islets at 2.8
mmol/l glucose but decreased at 16.7 mmol/l glucose. In contrast, oleate
oxidation was increased in islets pre-exposed to FFA. All of these
abnormalities were reversed in islets cultured for an additional 24 h with
high FFA or glucose concentrations in the presence of metformin (2.5
microg/ml). In conclusion, our data show that metformin is able to restore
the intracellular abnormalities of glucose and FFA metabolism and to
restore a normal secretory pattern in rat pancreatic islets whose secretory
function has been impaired by chronic exposure to elevated FFA or glucose
levels. These data raise the possibility that, in diabetic patients,
metformin (in addition to its peripheral effects) may have a direct
beneficial effect on the beta-cell secretory function.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Bikopoulos, A. da Silva Pimenta, S. C Lee, J. R Lakey, S. D Der, C. B Chan, R. B. Ceddia, M. B Wheeler, and M. Rozakis-Adcock
Ex vivo transcriptional profiling of human pancreatic islets following chronic exposure to monounsaturated fatty acids
J. Endocrinol.,
March 1, 2008;
196(3):
455 - 464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. Wajchenberg
{beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment
Endocr. Rev.,
April 1, 2007;
28(2):
187 - 218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Hull, Z.-P. Shen, M. R. Watts, K. Kodama, D. B. Carr, K. M. Utzschneider, S. Zraika, F. Wang, and S. E. Kahn
Long-Term Treatment With Rosiglitazone and Metformin Reduces the Extent of, but Does Not Prevent, Islet Amyloid Deposition in Mice Expressing the Gene for Human Islet Amyloid Polypeptide
Diabetes,
July 1, 2005;
54(7):
2235 - 2244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Marchetti, S. Del Guerra, L. Marselli, R. Lupi, M. Masini, M. Pollera, M. Bugliani, U. Boggi, F. Vistoli, F. Mosca, et al.
Pancreatic Islets from Type 2 Diabetic Patients Have Functional Defects and Increased Apoptosis That Are Ameliorated by Metformin
J. Clin. Endocrinol. Metab.,
November 1, 2004;
89(11):
5535 - 5541.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Matsui, Y. Terauchi, N. Kubota, I. Takamoto, K. Eto, T. Yamashita, K. Komeda, T. Yamauchi, J. Kamon, S. Kita, et al.
Pioglitazone Reduces Islet Triglyceride Content and Restores Impaired Glucose-Stimulated Insulin Secretion in Heterozygous Peroxisome Proliferator-Activated Receptor-{gamma}-Deficient Mice on a High-Fat Diet
Diabetes,
November 1, 2004;
53(11):
2844 - 2854.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C. Moore, M. A. Ugas, D. K. Hagman, S. D. Parazzoli, and V. Poitout
Evidence Against the Involvement of Oxidative Stress in Fatty Acid Inhibition of Insulin Secretion
Diabetes,
October 1, 2004;
53(10):
2610 - 2616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Kelpe, L. M. Johnson, and V. Poitout
Increasing Triglyceride Synthesis Inhibits Glucose-Induced Insulin Secretion in Isolated Rat Islets of Langerhans: A Study Using Adenoviral Expression of Diacylglycerol Acyltransferase
Endocrinology,
September 1, 2002;
143(9):
3326 - 3332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Patane, M. Anello, S. Piro, R. Vigneri, F. Purrello, and A. M. Rabuazzo
Role of ATP Production and Uncoupling Protein-2 in the Insulin Secretory Defect Induced by Chronic Exposure to High Glucose or Free Fatty Acids and Effects of Peroxisome Proliferator-Activated Receptor-{gamma} Inhibition
Diabetes,
September 1, 2002;
51(9):
2749 - 2756.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Severino, P. Brizzi, A. Solinas, G. Secchi, M. Maioli, and G. Tonolo
Low-dose dexamethasone in the rat: a model to study insulin resistance
Am J Physiol Endocrinol Metab,
August 1, 2002;
283(2):
E367 - E373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers
Metformin: An Update
Ann Intern Med,
July 2, 2002;
137(1):
25 - 33.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. S. Hermann and N. Wiernsperger
Impaired glucose tolerance and metformin: clinical and mechanistic aspects
The British Journal of Diabetes & Vascular Disease,
May 1, 2002;
2(3):
177 - 183.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Marchetti, R. Lupi, M. Federici, L. Marselli, M. Masini, U. Boggi, S. Del Guerra, G. Patane, S. Piro, M. Anello, et al.
Insulin Secretory Function Is Impaired in Isolated Human Islets Carrying the Gly972->Arg IRS-1 Polymorphism
Diabetes,
May 1, 2002;
51(5):
1419 - 1424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Lupi, F. Dotta, L. Marselli, S. Del Guerra, M. Masini, C. Santangelo, G. Patane, U. Boggi, S. Piro, M. Anello, et al.
Prolonged Exposure to Free Fatty Acids Has Cytostatic and Pro-Apoptotic Effects on Human Pancreatic Islets: Evidence that {beta}-Cell Death Is Caspase Mediated, Partially Dependent on Ceramide Pathway, and Bcl-2 Regulated
Diabetes,
May 1, 2002;
51(5):
1437 - 1442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Poitout and R. P. Robertson
Minireview: Secondary {beta}-Cell Failure in Type 2 Diabetes--A Convergence of Glucotoxicity and Lipotoxicity
Endocrinology,
February 1, 2002;
143(2):
339 - 342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Lupi, S. Del Guerra, V. Fierabracci, L. Marselli, M. Novelli, G. Patane, U. Boggi, F. Mosca, S. Piro, S. Del Prato, et al.
Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin
Diabetes,
February 1, 2002;
51(90001):
S134 - 137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Anello, V. Ucciardello, S. Piro, G. Patane, L. Frittitta, V. Calabrese, A. M. Giuffrida Stella, R. Vigneri, F. Purrello, and A. M. Rabuazzo
Chronic exposure to high leucine impairs glucose-induced insulin release by lowering the ATP-to-ADP ratio
Am J Physiol Endocrinol Metab,
November 1, 2001;
281(5):
E1082 - E1087.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Diabetes Association.
|
|
| |
|